BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ding XS, Mi L, Song YQ, Liu WP, Yu H, Lin NJ, Zhu J. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report. World J Clin Cases 2021; 9(21): 6041-6048 [PMID: 34368325 DOI: 10.12998/wjcc.v9.i21.6041]
URL: https://www.wjgnet.com/2307-8960/full/v9/i21/6041.htm
Number Citing Articles
1
Jiawen Huang, Juan Huang. Immune Checkpoint Inhibitors - New Insights and Recent Progress2023;  doi: 10.5772/intechopen.107435
2
Valli De Re, Ombretta Repetto, Lara Mussolin, Giulia Brisotto, Caterina Elia, Egesta Lopci, Emanuele S. G. d’Amore, Roberta Burnelli, Maurizio Mascarin. Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphomaFrontiers in Cell and Developmental Biology 2022; 10 doi: 10.3389/fcell.2022.965803
3
Yueru Ji, Jing Gao, Tong Wei, Miaowang Hao, Weiwei Qin. Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvementFrontiers in Oncology 2026; 15 doi: 10.3389/fonc.2025.1699475
4
Shihao Li, Yi Zhu, Zhijian Xu, Jianjun Liu, Hongwei Liu. Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature ReviewFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.866013